CorMedix Q3 net loss $9.7M; FDA inspections complete, launch targeted by Q1 2024

CorMedix Inc.

2023-Q3 EPS reported -$0.65

Net loss $9.7M ($0.17/sh) vs $6.9M ($0.17/sh) in Q3 2022; operating expenses up 50% to $10.5M.
Cash and short-term investments $86.6M as of Sept 30, 2023; sufficient for at least 12 months.
FDA completed preapproval inspections at primary CMO and key suppliers; no known deficiencies.
USPTO issued patent for DefenCath composition-of-matter (expiry April 2042).
Commercial launch targeted before end of Q1 2024 if FDA approval received.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

CorMedix Inc. reported nine months ended September 30, 2023 results: net income net loss of $31.6 million, or $0.65 per share, EPS $0.65 per share.

Period: nine months ended September 30, 2023
Net income: net loss of $31.6 million, or $0.65 per share
EPS: $0.65 per share
Result: reported results

Exact text from the filing

For the nine months ended September 30, 2023, CorMedix recorded a net loss of $31.6 million, or $0.65 per share, compared with a net loss of $21.5 million, or $0.54 per share, in the first nine months of 2022.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

CorMedix Inc. reported third quarter ended September 30, 2023 results: net income net loss of $9.7 million, or $0.17 per share, EPS $0.17 per share.

Period: third quarter ended September 30, 2023
Net income: net loss of $9.7 million, or $0.17 per share
EPS: $0.17 per share
Result: reported results

Exact text from the filing

For the third quarter of 2023, CorMedix recorded a net loss of $9.7 million, or $0.17 per share, compared with a net loss of $6.9 million, or $0.17 per share, in the third quarter of 2022.

View on SEC.gov

Browse all earnings releases →

CorMedix Inc. filing history →

Source: SEC EDGAR

accession 0001213900-23-086937

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.